{"entity":{"id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","aka":[],"tldr":"A phase 2 trial of IMC-001 in advanced solid tumours, run by ImmuneOncia Therapeutics Inc., now recruiting.","summary":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor is a phase 2 interventional study registered as NCT06365840 by ImmuneOncia Therapeutics Inc., with 30 participants planned, started 2025-01-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: IMC-001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06365840","url":"https://clinicaltrials.gov/study/NCT06365840"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06365840","phase":"2","setting":"PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR","sponsor":"ImmuneOncia Therapeutics Inc.","enrolled":30,"outcomes":[]},"route":"/trials/nct06365840/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}]}}